Parkinson’s research Archives

Comic-style illustration of Michael J. Fox pointing toward Parkinson’s research and clinical trial displays, surrounded by scientists, patients and investors, with upward arrows symbolizing progress and investor optimism.

The Michael J. Fox Foundation Is Building Parkinson’s Next Chapter. Investors Have Reason to Pay Attention. -( $ABBV $IBB $SER $XBI )

by John F. Heerdink, Jr. 5 days ago 289Views 0Likes

Better biomarkers, new FDA approvals and an emerging delivery pipeline strengthen the case for Parkinson’s innovation, with AbbVie and Serina Therapeutics offering distinct investment angles. The most compelling Parkinson’s investment story does not begin with a stock chart. It begins with a…

Serina Therapeutics Puts Advanced Parkinson’s Disease in the Spotlight – Thursday, September 24

by John F. Heerdink, Jr. September 23, 2026 184Views 0Likes

Parkinson’s disease is one of medicine’s most stubborn commercial and scientific frontiers, and Serina Therapeutics, Inc. (NYSE American: SER) is positioning its lead program, SER-252, squarely in the middle of that opportunity. The clinical-stage biotechnology company has opened registration for a Tribe Public CEO…

Serina Therapeutics Brings a Fresh Dose of Momentum to Advanced Parkinson’s Care -( $SER $PFE $XBI )

by John F. Heerdink, Jr. September 21, 2026 355Views 0Likes

Serina Therapeutics, Inc. (NYSE American: SER) is approaching a consequential clinical milestone with SER-252, its long-acting POZ-apomorphine candidate for advanced Parkinson’s disease, now advancing into Cohort 2 of a registrational Phase 1b study. For many, the appeal is not simply that Serina is pursuing…

Tag: Parkinson’s research

The Michael J. Fox Foundation Is Building Parkinson’s Next Chapter. Investors Have Reason to Pay Attention. -( $ABBV $IBB $SER $XBI )

Serina Therapeutics Puts Advanced Parkinson’s Disease in the Spotlight – Thursday, September 24

Serina Therapeutics Brings a Fresh Dose of Momentum to Advanced Parkinson’s Care -( $SER $PFE $XBI )

Your Guide To Staying Informed In The Markets